Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protein aggregate myopathies.

M C Sharma1, H H Goebel

  • 1All India Institute of Medical Sciences, New Delhi.

Neurology India
|October 19, 2005
PubMed
Summary
This summary is machine-generated.

Protein aggregate myopathies (PAM) involve abnormal protein buildup in muscles. Research categorizes PAM into four types, suggesting distinct causes related to protein degradation or developmental defects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuronal ceroid lipofuscinosis (NCL) is caused by the entire deletion of CLN8 in the Alpenländische Dachsbracke dog.

Molecular genetics and metabolism·2016
Same author

Protein aggregation in inclusion body myositis, a sporadic form among protein aggregate myopathies, and in myofibrillar myopathies--a comparative study.

Romanian journal of internal medicine = Revue roumaine de medecine interne·2011
Same author

Familial reducing body myopathy with cytoplasmic bodies and rigid spine revisited: identification of a second LIM domain mutation in FHL1.

Neuropediatrics·2010
Same author

CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL.

Neurology·2010
Same author

Macrophagic myofasciitis plus (distinct types of muscular dystrophy).

Neuropediatrics·2010
Same author

Consequences of mutations within the C terminus of the FHL1 gene.

Neurology·2009
Same journal

A Life in Service of Neuroscience, Healing, and Teaching.

Neurology India·2026
Same journal

IN MEMORIAM.

Neurology India·2026
Same journal

Extensive Diffusion Restriction of White Matter, Midbrain, and Basal ganglia in a Neonate with Refractory Hypoglycemic Seizures.

Neurology India·2026
Same journal

CHD2-Related Developmental Epileptic Encephalopathy and Angelman Syndrome in a Girl: A Double Jeopardy.

Neurology India·2026
Same journal

Cerebral Schistosomiasis Mimicking Multiple Intracranial Metastases.

Neurology India·2026
Same journal

Extrusion of Spinal Implants Through the Overlying Skin: A Rare Epiphenomenon of Metal Allergy.

Neurology India·2026
See all related articles

Area of Science:

  • Muscle Diseases
  • Neurology
  • Genetics

Background:

  • Protein aggregate myopathies (PAM) are a class of muscle disorders.
  • Characterized by the accumulation of intrinsic proteins within muscle fibers.
  • These myopathies present with distinct structural abnormalities.

Purpose of the Study:

  • To categorize and describe the emerging group of protein aggregate myopathies.
  • To explore the potential pathogenetic mechanisms underlying different forms of PAM.
  • To highlight the diagnostic approaches for identifying these conditions.

Main Methods:

  • Classification of PAM into four major groups: desmin-related myopathies (DRM), hereditary inclusion body myopathies, actinopathies, and myosinopathies.
  • Analysis of genetic mutations associated with specific PAM forms (e.g., ACTA1, MYH-7).

Related Experiment Videos

  • Immunohistochemistry and molecular analysis for protein identification and gene correlation.

    • Main Results:

    • PAM forms 1 and 2 (DRM, inclusion body myopathies) likely stem from impaired protein degradation.
    • PAM forms 3 and 4 (actinopathies, myosinopathies) may result from anabolic or developmental defects.
    • Specific genes like ACTA1 and MYH-7 are implicated in actinopathies and myosinopathies, respectively.

    Conclusions:

    • The pathogenetic mechanisms of protein aggregation in PAM, whether catabolic or anabolic, require further elucidation.
    • The composition of inclusions in various congenital myopathies remains to be clarified.
    • Immunohistochemistry and molecular genetics are key tools for diagnosing PAM.